Cartwright Law News
Personal Injury
Wrongful Death
Motor Vehicle Accidents
Products Liability
Employment Law
Nursing Home Abuse

FDA Alert – Z-Max Antibiotic May Affect Heart Rythym Fatally

*An FDA Alert! – The FDA is warning the public that azithromycin (Zithromax or Zmax) can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm. Patients at particular risk for developing this condition include those with known risk factors such as existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias.  FDA has issued a Drug Safety Communication today as a result of our review of a study by medical researchers as well as another study by a manufacturer of the drug that assessed the potential for azithromycin to cause abnormal changes in the electrical activity of the heart.

The FDA previously released a Statement on May 17, 2012, about a study that compared the risks of cardiovascular death in patients treated with the antibacterial drugs azithromycin, amoxicillin, ciprofloxacin (Cipro), and levofloxacin (Levaquin), or no antibacterial drug. The study reported an increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug. The risks of cardiovascular death associated with levofloxacin treatment were similar to those associated with azithromycin treatment.

Azithromycin is marketed under the brand names Zithromax and Zmax. FDA-approved indications for azithromycin include: acute bacterial exacerbations of chronic obstructive pulmonary disease, acute bacterial sinusitis, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, urethritis and cervicitis, genital ulcer disease.

Health care professionals should consider the risk of torsades de pointes and fatal heart rhythms with azithromycin when considering treatment options for patients who are already at risk for cardiovascular events. FDA notes that the potential risk of QT prolongation with azithromycin should be placed in appropriate context when choosing an antibacterial drug: Alternative drugs in the macrolide class, or non-macrolides such as the fluoroquinolones, also have the potential for QT prolongation or other significant side effects that should be considered when choosing an antibacterial drug.

* – From the FDA Website.

The Cartwright Law Firm works to keep the public up-to-date and aware of evolving health risks wherever they may arise. We urge you to stay tuned for more updates on this issue as it begins to be better understood by regulators and investigators. Like us on Facebook, and add us to your RSS feed for frequent updates on FDA Alerts and other health and safety alerts!

Our Office Locations
San Francisco Office

222 Front Street, 5th Floor
San Francisco, CA 94111

Phone: 415-433-0444

Fax: 415-433-0449

Go To Map
Vacaville Office

419 Mason Street, Suite 207
Vacaville, CA 95688

Phone: 707-901-3020

Fax: 415-433-0449

Go To Map
Discovery Bay Office

2465 Discovery Bay Blvd.,
Suite 300 Discovery Bay, CA 94505

Phone: 925-265-4009

Fax: 415-433-0449

Go To Map
Santa Rosa Office

703 2nd Street, Suite 119
Santa Rosa, CA 95404

Phone: 707-266-7540

Fax: 415-433-0449

Go To Map